Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008, 358: 1160–1174. 10.1056/NEJMra0707704
Article
CAS
PubMed
Google Scholar
Zhang BH, Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000, 19: 5429–5439. 10.1093/emboj/19.20.5429
Article
CAS
PubMed Central
PubMed
Google Scholar
Turjanski AG, Vaque JP, Gutkind JS: MAP kinases and the control of nuclear events. Oncogene 2007, 26: 3240–3253. 10.1038/sj.onc.1210415
Article
CAS
PubMed
Google Scholar
Pratilas CA, Solit DB: Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2007, 2: 121–134. 10.2174/157488707780599393
Article
CAS
PubMed
Google Scholar
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, et al.: BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364: 2305–2315. 10.1056/NEJMoa1014209
Article
CAS
PubMed Central
PubMed
Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–954. 10.1038/nature00766
Article
CAS
PubMed
Google Scholar
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88: 5399–5404. 10.1210/jc.2003-030838
Article
CAS
PubMed
Google Scholar
Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12: 245–262. 10.1677/erc.1.0978
Article
CAS
PubMed
Google Scholar
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26: 5705–5712. 10.1200/JCO.2008.18.0786
Article
CAS
PubMed
Google Scholar
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101: 1308–1324. 10.1093/jnci/djp280
Article
CAS
PubMed Central
PubMed
Google Scholar
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature reviews 2009, 6: 519–527.
CAS
PubMed
Google Scholar
Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89: 5175–5180. 10.1210/jc.2003-032221
Article
CAS
PubMed
Google Scholar
Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH: Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004, 10: 2761–2765. 10.1158/1078-0432.CCR-03-0273
Article
CAS
PubMed
Google Scholar
Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV: BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006, 15: 136–143. 10.1097/01.pdm.0000213461.53021.84
Article
CAS
PubMed
Google Scholar
Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N: Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009, 11: 140–147. 10.2353/jmoldx.2009.080100
Article
CAS
PubMed Central
PubMed
Google Scholar
Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG: Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 2004, 18: 349–352. 10.1016/j.mcp.2004.05.004
Article
CAS
PubMed
Google Scholar
Pinzani P, Santucci C, Mancini I, Simi L, Salvianti F, Pratesi N, Massi D, De Giorgi V, Pazzagli M, Orlando C: BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta 2011, 412: 901–905. 10.1016/j.cca.2011.01.014
Article
CAS
PubMed
Google Scholar
Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009, 133: 1600–1606.
CAS
PubMed
Google Scholar
Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL: Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007, 9: 272–276. 10.2353/jmoldx.2007.060133
Article
CAS
PubMed Central
PubMed
Google Scholar
Melanie JP, Mary Frances M: The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol 2005, 23: 91–93. 10.1002/hon.761
Article
CAS
Google Scholar
Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 29: 132. 10.1186/1756-9966-29-132
Article
PubMed Central
PubMed
CAS
Google Scholar
Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R: Detection of BRAF V600E mutation by pyrosequencing. Pathology 2008, 40: 295–298. 10.1080/00313020801911512
Article
CAS
PubMed
Google Scholar
Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH: Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab 2012, 97: 2299–2306. 10.1210/jc.2011-3135
Article
CAS
PubMed
Google Scholar
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63: 1454–1457.
CAS
PubMed
Google Scholar
Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63: 4561–4567.
CAS
PubMed
Google Scholar
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95: 625–627. 10.1093/jnci/95.8.625
Article
CAS
PubMed
Google Scholar
Trovisco V, de Castro Vieira I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202: 247–251. 10.1002/path.1511
Article
CAS
PubMed
Google Scholar
Kim KH, Kang DW, Kim SH, Seong IO, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45: 818–821.
Article
CAS
PubMed
Google Scholar
Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, Westra J, Frebourg T, Espin E, Armengol M, et al.: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004, 41: 664–668. 10.1136/jmg.2004.020651
Article
CAS
PubMed Central
PubMed
Google Scholar
Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R, et al.: BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005, 24: 3995–3998. 10.1038/sj.onc.1208569
Article
CAS
PubMed
Google Scholar
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al.: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105: 3041–3046. 10.1073/pnas.0711741105
Article
CAS
PubMed Central
PubMed
Google Scholar
Nikiforova MN, Nikiforov YE: Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008, 8: 83–95. 10.1586/14737159.8.1.83
Article
CAS
PubMed
Google Scholar
Benoit NE, Goldenberg D, Deng SX, Rosenbaum E, Cohen Y, Califano JA, Shackelford WH, Wang XB, Sidransky D: Colorimetric approach to high-throughput mutation analysis. Biotechniques 2005, 38: 635–639. 10.2144/05384PF01
Article
CAS
PubMed
Google Scholar
Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A: Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 2011, 13: 23–28. 10.1016/j.jmoldx.2010.11.007
Article
CAS
PubMed Central
PubMed
Google Scholar
Morandi L, de Biase D, Visani M, Cesari V, De Maglio G, Pizzolitto S, Pession A, Tallini G: Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. PLoS One 2012, 7: e36084. 10.1371/journal.pone.0036084
Article
CAS
PubMed Central
PubMed
Google Scholar
Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH: Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab 2012, 97: 2299–2306. 10.1210/jc.2011-3135
Article
CAS
PubMed
Google Scholar